The Department of Health and Human Services (HHS), led by Health Secretary Robert F. Kennedy Jr., has submitted an interim access policy to the White House that aims to permit specialty pharmacies to compound specific peptides. These peptides, such as BPC-157, are not FDA-approved for the uses promoted by wellness advocates, including muscle building and injury healing.
The FDA has previously flagged these substances as risky, citing potential contamination and other health concerns. However, the proposed policy reflects a shift towards easing access to these products, which are increasingly sought after by consumers turning to unregulated sources.
The market for peptides is estimated to be worth between $2 billion and $3 billion, attracting interest from major telehealth providers like Hims & Hers and Noom. The move has been met with enthusiasm from proponents of the wellness movement, who view it as a victory for medical freedom.
The implications of this policy could reshape the landscape of peptide availability and regulation in the U.S., potentially leading to increased sales for compounding pharmacies and related businesses